About

Company history

AriBnC Co., Ltd. was founded on 1 September 2021 and opened for business the same day. The head office has been in Yongin-si, Gyeonggi-do throughout. The milestones below are grouped into three periods: Foundation (2021), Expansion (2022–2025) and Acceleration (2025–2026).

About AriBnCCredentials

Why three periods

Foundation 2021 / Expansion 2022–2025 / Acceleration 2025–2026

2021 was the year the company and its Corporate Affiliated Research Institute were established. Between 2022 and 2025 AriBnC put in place the qualifications and the sites it needs to take on studies under contract — MSIT specialised research business registration, Venture Company confirmation, KoNECT CRO registration and the UNIST Research Institute (the UNIST site of our Corporate Affiliated Research Institute). From 2025 the company began AI and data-analysis research alongside its human application studies and regulatory work.

Foundation — 2021

  1. Company founded and opened for business on 1 September. The registered name is 주식회사 아리비앤씨; in English, AriBnC Co., Ltd. The brand line is ‘AriBnC’; BnC first stood for Bio & CK Story, then for Bio & CRO, and since 2026 has stood for Bio & Computing. The head office is in Yongin-si, Gyeonggi-do; the company's main business is contract research — human application studies and clinical trials.

  2. Corporate Affiliated Research Institute recognised by the Korea Industrial Technology Association (KOITA), No. 2021116297. The company's in-house research organisation was registered.

Expansion — 2022–2025

  1. Registered as a specialised research business with the Ministry of Science and ICT (MSIT).

  2. Venture Company confirmation obtained (a Korean government scheme).

  3. Patent application KR 10-2022-0186215 filed — a health functional food composition for improving sleep.

  4. Registered as a CRO with the Korea National Enterprise for Clinical Trials (KoNECT), meeting the registration requirements for contracting drug and medical-device trials.

  5. Patent No. 10-2536484 granted — an optical blood-glucose meter structure (filed January 2023).

  6. Moved to a co-CEO structure under Yunsuk Chun and Jongkyu Kim, dividing responsibility for study conduct and regulatory affairs.

  7. Opened the UNIST Research Institute, handling probiotic strain development and in-house lab-scale research.

  8. Trademark ‘BCS-001F’ registered (No. 40-2209581); ‘BCS-002D’ followed in August (No. 40-2230194).

  9. MFDS approval of a digital therapeutic clinical trial plan: digital therapeutic (medical device) for a CNS disorder.

  10. Black cumin extract (FJ) recognised as a functional ingredient for health functional foods — MFDS No. 2025-3. The company holds the recognition.

  11. Probiotic strain Limosilactobacillus reuteri NGM4-42-L211 deposited at KCTC for patent purposes (KCTC 16358BP).

  12. Probiotic strain Lactiplantibacillus plantarum NGM1-12-L209 deposited at KCTC for patent purposes. In the same month a patent application was filed for a composition using Lactobacillus plantarum to improve the bioavailability of vitamin C (KR 10-2025-0101866).

Acceleration — 2025–2026

  1. Patent application KR 10-2025-0108178 filed — AI-based gut-microbiome profile prediction and personalised probiotics.

  2. Patent application KR 10-2025-0215909 filed — Lactiplantibacillus plantarum NGM1-12-L209, a strain with improved survival in the gastrointestinal tract and improved adhesion to intestinal epithelial cells.

  3. Seung Ho Jung, PhD, joined as Vice President.

  4. Probiotic strain Lactobacillus paragasseri NGM2-43-L201 deposited at KCTC for patent purposes (KCTC 16690BP) — our third deposited strain.

  5. Patent No. 10-2947837 granted — a composition using Lactobacillus plantarum to improve the bioavailability of vitamin C (filed July 2025).

  6. ABCI, the AI-Bio Convergence Institute, established — the unit that researches health-data analysis methods and AI prediction models.

  7. Agreement signed under the MOTIR industrial-innovation national R&D programme, for a term of 30 months.

  8. Patent application KR 10-2026-0099786 filed — AI-based non-invasive lifelog liver-indicator prediction and health-behaviour recommendation.

  9. Developed the AI system that produces the Liver Wellness Index. Release of a wellness information app for Android and iOS is in preparation for Korea, Japan and Southeast Asia.

An office at the Yongin head office — monitors on arms, a sit-stand desk and cabinets by the window

To see how the qualifications and sites listed here are used on actual projects, review our credentials or send us an outline of your project.

CredentialsLeadershipContact us